Close
Antibody based drugs can disturb serological blood group testing since the examined antigens can be masked by the therapeutic antibodies. An anti-CD38 antibody for treatment of multiple myeloma shows a strong interference in the indirect antiglobulin test (IAT) where most of the reactions turn to unspecifically (wrong) positive. The time consuming standard technique using Dithiothreitol (DTT) counteracts the interference but has major drawbacks like destruction of Kel antigens or hemolysis. The imusyn DaraEx compound inhibits the agglutination effect of anti-CD38 in IAT without side effects.
We are happy to announce that the anti-CD38 antibody neutralizing agent DaraEx has now an improved functionality by changing the chemistry from a F(ab)2 fragment to a Fab fragment. The new uniform express protocol does not need a pre-incubation of the test cells with DaraEx anymore. Instead DaraEx can be added directly on the gel card without any delay in the indirect antiglobulin test (IAT).
